Editorial Commentary: Should “heterogeneous response” be considered as new category for assessing treatment response in patients with breast cancer?
Sofia C. Vaz (Champalimaud Clinical Center, Leiden University Medical Center)
David Groheux (Saint-Louis Hospital, Centre d’Imagerie Radio-Isotopique (CIRI), University Paris Diderot and Inria)
Thiemo van Nijnatten (Maastricht University Medical Center)
Lidija Antunovic (Ospedale San Raffaele)
Fatima Cardoso (Champalimaud Clinical Center, Advanced Breast Cancer Global Alliance)
Felix Mottaghy (Maastricht University Medical Center, Maastricht University, RWTH Aachen University)
Maria Joao Cardoso (Universidade Nova de Lisboa, Champalimaud Clinical Center)
Christopher Riedl (ImagingWest)
Lioe Fee de Geus-Oei (University of Twente, Leiden University Medical Center, TU Delft - RST/Radiation, Science and Technology)
Gary A. Ulaner (Hoag Family Cancer Institute, University of Southern California)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.